NCT/Study#

MK1084-001

A phase I, open-label, multicenter study to assess safety, tolerability, PK and efficacy of MK-1084 as monotherapy and in combination with pembrolizumab in subjects with KRASG12C mutant advanced solid tumors 1084-001

A phase I, open-label, multicenter study to assess safety, tolerability, PK and efficacy of MK-1084 as monotherapy and in combination with pembrolizumab in subjects with KRASG12C mutant advanced solid tumors 1084-001

DISEASE GROUP:
Phase 1
current phase:
Phase I
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: